| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |